Back to search

Democritus University of Thrace (DUTH)

Αγγείωση και υποξία σε όγκους του γυναικολογικού συστήματος

Abstract

dc:description

Angiogenesis is a term used for the development of a complicated process, occurring both in health and disease. Angiogenesis can be divided into: a. early embryonic, it is taking place during differentiation of the multipotential mesenchymal cells in the formation of the vasculature network in the liver, lungs and pancreas. b. secondary angiogenesis, in natural processes (maturation of the corpus luteum, development of trophoblast-placenta, menstrual period), in pathological processes (wound repair in the adult, myocardial infarction, cancer) of the human organism. c. cancer angiogenesis, neoplasms are extended beyond their borders due to the presence of newly formed capillaries. In their early stages, tumors are being limited within 2-3mm, in order for those limits to be overcome, new blood vessels need to be formed in the periphery for the tumor to expand. The secretion of angiogenic-antigenic factors, the disturbance of the balance between these factors, the stimulation of cells (e.g. macrophages), the degradation of the extra cellular matrix, the vigorous proliferation of the endothelial cells are some of the facts that push towards direction of the angiogenic phenotype. The architecture of the vasculature is chaotic and irregular. The vessels’ diameter is variable; many capillaries follow abnormal branching and blind endings. There is a difference on the vessels’ diameter from point to point along their course. Anastomoses are variable, circulation is chaotic and edemas are very common. In our research we studied the titers (in serum with ELISA and in tissue with immunohistochemistry) of the vascular endothelium growth factor VEGF and lactate dehydrogenase (LDH). Both factors are thought to be markers of angiogenesis and hypoxia in benign and malignant disease in the female system. Furthermore the titer of HIF-a (it is being induced by hypoxia and activates the translation of the VEGF and LDH genes) was studied in the tissues. Generally VEGF concentration was statistically higher in malignant cases, whilst in benign cases the VEGF concentrations were close to the control group. VEGF levels were associated neither with age nor with hemoglobin or the platelet count in the blood. The results of our research on endometrial cancer patients showed increased serum VEGF levels compared to patients with fibromyomas or healthy subjects. The presence of the VEGF molecule was independent either of the endometrial depth invasion or the patients’ age. Patients with endometrial cancer, their serum LDH was significantly higher compared to the simple cysts and control group. The ovarian adenomas study group showed high VEGF and LDH. VEGF levels on patients with breast cancer were high compared to the control group. Similar results (high VEGF) were observed on patients with benign breast disease. Breast cancer patients with larger tumors had the tendency towards elevated serum VEGF levels, the difference was insignificant though. What is really surprising is that even higher VEGF levels were detected in patients with free (without metastases) lymph nodes. The LDH marker was higher both in malignant and benign breast groups compared to the control group. The activated receptors (VEGFR-2/KDR) for VEGF were in high numbers on histology specimens of endometrial and breast cancer. High LDH transcription activity was observed in cancer tissues. The presence of the HIF-1a transcription factor, in hypoxia conditions, coincides with the expression of the activated receptors VEGFR-2/KDR in cancer tissues. Lactate dehydrogenase LDH and vascular endothelium growth factor VEGF, the two important markers are significantly increased both in cancer tissues and serum. The close transcriptional correlation between the two proteins and the HIF factor undermines the importance of the aforementioned HIF molecule, in the biology of the neoplasms. Elevated titers of the two markers do not necessarily indicate the existence of malignancy, since both molecules increase in benign diseases of the ovary and the breast. They do play a major role in angiogenesis, but can not be used in the differential diagnosis of tumors.

Degree

thesis:*
Grantor dc:publisher
Democritus University of Thrace (DUTH)
Year dc:date
2007

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kontomanolis, Emmanouil
  • Κοντομανώλης, Εμμανουήλ

Subjects

dc:subject × 22

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/20989

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kontomanolis, Emmanouil; Κοντομανώλης, Εμμανουήλ. Αγγείωση και υποξία σε όγκους του γυναικολογικού συστήματος. Democritus University of Thrace (DUTH), 2007. http://hdl.handle.net/10442/hedi/20989